UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma

Cancer research (Chicago, Ill.), 2015-04, Vol.75 (8), p.1675-1681

2015

Volltextzugriff (PDF)

Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011

Journal of clinical oncology, 2002-09, Vol.20 (18), p.3878-3884

2002

Volltextzugriff (PDF)

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy

International reviews of immunology, 2012-04, Vol.31 (2), p.119-132

2012

Volltextzugriff (PDF)

Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth

Molecular cancer therapeutics, 2016-12, Vol.15 (12), p.2835-2844

2016

Volltextzugriff (PDF)

Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011

Journal of clinical oncology, 2001-08, Vol.19 (16), p.3611-3621

2001

Volltextzugriff (PDF)

C-Terminal Threonine Phosphorylation Activates ERM Proteins to Link the Cell's Cortical Lipid Bilayer to the Cytoskeleton

Biochemical and biophysical research communications, 1998-12, Vol.253 (3), p.561-565

1998

Volltextzugriff (PDF)

Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia

Cancer, 2017-08, Vol.123 (16), p.3061-3072

2017

Volltextzugriff (PDF)

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood, 2013-10, Vol.122 (14), p.2412-2424

2013

Volltextzugriff (PDF)

Abstract 4564: Inhibitory effects of the BTK inhibitor, ibrutinib, on Her2 amplified breast cancer growth, cell cycle progression and clonogenicity

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4564-4564

2014

Volltextzugriff (PDF)

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

The Journal of clinical investigation, 2014-11, Vol.124 (11), p.4867-4876

2014

Volltextzugriff (PDF)

Abstract C258: BTK inhibitor ibrutinib inhibits breast cancer growth by inhibiting ErbB2 kinase

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C258-C258

2013

Volltextzugriff (PDF)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

British journal of haematology, 2018-03, Vol.180 (6), p.821-830

2018

Volltextzugriff (PDF)

Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols

Urologic oncology, 2008-11, Vol.26 (6), p.610-615

2008

Volltextzugriff (PDF)

Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia

The New England journal of medicine, 2000-12, Vol.343 (24), p.1750-1757

2000

Volltextzugriff (PDF)

Interferon effects upon fluorouracil metabolism by HL-60 cells

Biochemical and biophysical research communications, 1989-09, Vol.163 (2), p.867-874

1989

Volltextzugriff (PDF)

Abstract 3519: Mobilization of follicular lymphoma cells into peripheral blood following BTK inhibition by ibrutinib

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3519-3519

2013

Volltextzugriff (PDF)

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Cancer, 2002-01, Vol.94 (1), p.25-36

2002

Volltextzugriff (PDF)

Abstract 396: Ibrutinib exerts potent antifibrotic activity in a mouse model of pancreatic adenocarcinoma

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.396-396

2015

Volltextzugriff (PDF)

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Blood, 2012-11, Vol.120 (21), p.4039-4039

2012

Volltextzugriff (PDF)

Egress of CD19+CD5+ Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

Blood, 2011-11, Vol.118 (21), p.954-954

2011

Volltextzugriff (PDF)

Protein kinase C-theta phosphorylation of moesin in the actin-binding sequence

The Journal of biological chemistry, 1998-03, Vol.273 (13), p.7594-7603

1998

Volltextzugriff (PDF)

Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in combination with gemcitabine in patients with advanced pancreatic cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15014-e15014

2013

Volltextzugriff (PDF)

Leukemic T-PLL Cells Exhibit Short and Narrowly Distributed Telomere Lengths and High Telomerase Activities, Associated with Rapid and Dose-Dependent Cell Death Following Telomerase Inhibition by Imetelstat Sodium

Blood, 2009-11, Vol.114 (22), p.2647-2647

2009

Volltextzugriff (PDF)

1 – 25 von 257

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(226)
Mit Volltextzugriff
(239)

Publikationsform

Sprache

Englisch
(247)
Französisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy

Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth

Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011

C-Terminal Threonine Phosphorylation Activates ERM Proteins to Link the Cell's Cortical Lipid Bilayer to the Cytoskeleton

Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Abstract 4564: Inhibitory effects of the BTK inhibitor, ibrutinib, on Her2 amplified breast cancer growth, cell cycle progression and clonogenicity

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

Abstract C258: BTK inhibitor ibrutinib inhibits breast cancer growth by inhibiting ErbB2 kinase

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols

Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia

Interferon effects upon fluorouracil metabolism by HL-60 cells

Abstract 3519: Mobilization of follicular lymphoma cells into peripheral blood following BTK inhibition by ibrutinib

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Abstract 396: Ibrutinib exerts potent antifibrotic activity in a mouse model of pancreatic adenocarcinoma

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Egress of CD19+CD5+ Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Protein kinase C-theta phosphorylation of moesin in the actin-binding sequence

Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in combination with gemcitabine in patients with advanced pancreatic cancer

Leukemic T-PLL Cells Exhibit Short and Narrowly Distributed Telomere Lengths and High Telomerase Activities, Associated with Rapid and Dose-Dependent Cell Death Following Telomerase Inhibition by Imetelstat Sodium

Suchergebnisse filtern